Items where authors include "Ottensmeier, C.H.H."

Conference or Workshop Item

Gkountouras, G. orcid.org/0000-0003-2093-5359, Meads, D., Mujica-Mota, R. et al. (16 more authors) (2025) LBA2 The DANTE phase III trial comparing 1 year versus 2 years of anti-PD1 immunotherapy as first-line treatment for metastatic melanoma: Health economics analysis. In: ESMO Immuno-Oncology Congress 2025, 10-12 Dec 2025, London, United Kingdom.

Proceedings Paper

Danson, S., Collinson, M., Plummer, E.R. et al. (17 more authors) (2025) Comparison of 1 year versus minimum 2 years of anti-PD1-based immunotherapy as first-line treatment for metastatic melanoma: Results of the DANTE phase III trial. In: Journal of Clinical Oncology. 2025 ASCO Annual Meeting II, 30 May - 03 Jun 2025, Chicago, USA. American Society of Clinical Oncology (ASCO) .